Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

NCT00337610 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
DRUG: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day

Sponsor

Merck Sharp & Dohme LLC